Longevity & Cardiovascular Health
Your cardiovascular system ages long before you feel it.
NOVOS Core is a longevity formulation studied in a randomized, double-blind, placebo-controlled human trial for its effects on measures of healthy vascular function: arterial flexibility, endothelial responsiveness, and blood pressure within the normal range.
+2.9pts
FMD vs placebo
−1.18m/s
PWV vs placebo
−6.1mmHg
SBP vs placebo*
Placebo-adjusted differences at six months in biomarkers of vascular function. NOVOS Core is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.
As featured in
NOVOS Core
The exact finished formulation used in the trial.
No isolated single ingredient, no research-only version. The clinical study evaluated the complete NOVOS Core product as sold, one flavored powder sachet mixed into water, once a day.
- 12 ingredients in a single daily drink
- Third-party tested for purity and potency
- Vegan, non-GMO, no added sugar or artificial sweeteners
- Manufactured in the USA in a cGMP facility
NOVOS Core ingredient panel
The 12 ingredients in the finished formulation evaluated in the trial.
- Vitamin C
- Magnesium
- Glycine
- Calcium Alpha-Ketoglutarate
- GreenGrown® Glucosamine Sulfate
- Rhodiola Rosea Root Extract
- L-Theanine
- Hyaluronic Acid
- Fisetin
- Organic Ginger Root Extract
- Pterostilbene
- Lithium Aspartate
Longer-horizon risk
Cardiovascular risk is now assessed from age 30, because the biology starts much earlier than the diagnosis.
In 2026, updated ACC/AHA guidance recommends estimating both 10-year and 30-year cardiovascular risk beginning at age 30. The shift reflects a simple reality of the science: cardiovascular disease develops over decades, and long-term risk becomes meaningful long before it becomes visible.
20s
Silent groundwork
Arterial changes can begin decades before anything is detectable in ordinary bloodwork or felt as a symptom.
30
The new starting line
2026 ACC/AHA guidance recommends estimating both 10-year and 30-year cardiovascular risk starting at age 30.
40s–50s
Where most people start
Conventional attention often begins only once risk markers move, years after vascular changes have accumulated.
Invisible infrastructure
Circulation isn’t a heart story. It’s a whole-body story.
Roughly 60,000 miles of blood vessels reach nearly every cell you have. When researchers study vascular function, they’re studying the delivery system that supports how the rest of the body performs.
Cognitive function
The brain is one of the most perfusion-dependent organs in the body, relying on steady cerebral blood flow.
Physical performance
Working muscle depends on how effectively vessels dilate to deliver oxygen and nutrients on demand.
Energy & stamina
Cellular energy production requires reliable oxygen delivery through the smallest capillaries.
Skin quality
Dermal microcirculation supports nutrient delivery to skin tissue and normal skin function.
Eye health
Retinal tissue is served by an exceptionally fine vascular network sensitive to blood-flow changes.
Kidney function
Filtration depends on vascular flow; the kidneys receive a substantial share of cardiac output.
These descriptions explain the physiological role of circulation in the body. They are not claims that NOVOS Core treats, prevents, or improves any specific organ condition.
What the researchers measured
Three established measures of vascular function.
Rather than relying on self-reported feelings, the trial used objective vascular biomarkers routinely used in cardiovascular research.
Flow-mediated dilation
Endothelial Function
How well an artery widens when blood flow increases, a non-invasive measure of endothelial function.
The endothelium is the single-cell lining that governs how vessels relax, dilate, and respond to demand.
+2.9pts
placebo-adjusted difference at 6 months
Pulse Wave Velocity
Vascular Flexibility
The speed at which a pressure wave travels along the arteries. Stiffer arteries transmit it faster.
Arterial flexibility is one of the most studied structural properties of the vascular system.
−1.18m/s
placebo-adjusted difference at 6 months
Systolic blood pressure
Blood Pressure
The pressure inside arteries when the heart contracts, measured here entirely within the normal range.
Blood pressure within a healthy range is part of normal cardiovascular function.
−6.1mmHg
placebo-adjusted difference at 6 months
*Participants began and remained within the normal blood-pressure range. Trial did not assess cardiovascular events or disease prevention. These are biomarkers of vascular function; biomarker changes are not the same as reduced disease risk.
The clinical study
An independent, university-run randomized controlled trial.
The study was conducted by researchers at the University of Surrey and led by Professor Christian Heiss, a vascular medicine researcher and one of the field’s most-published authors on flow-mediated dilation methodology.
- Design
- Randomized, double-blind, placebo-controlled
- Institution
- University of Surrey, United Kingdom
- Duration
- 6 months of daily supplementation
- Participants
- Generally healthy adults aged 40+
- Product tested
- Complete finished NOVOS Core formulation
- Registration
- NCT06145087
Results are available as an SSRN preprint. The manuscript is currently under peer review, and findings should be interpreted accordingly.
“Very few supplements are ever tested this way: as the complete finished product, in a randomized placebo-controlled design, using objective vascular measurements.”
Professor Christian Heiss · Principal investigator, University of Surrey
Statement refers to study methodology. It is not a claim that NOVOS Core treats or prevents disease.
Primary measure
Flow-mediated dilation over six months
FMD was measured at baseline, one hour after a single dose, and again after six months of daily use in a fasted state. Values below are the reported readout at each timepoint, not a live chart.
Baseline
5.55%
vs 5.05% placebo
Acute (1 hour)
8.95%
vs 4.85% placebo
6 months
8.1%
vs 4.95% placebo
Data from the randomized, double-blind, placebo-controlled University of Surrey trial. FMD is a biomarker of endothelial function; a change in FMD is not a measure of disease risk.
Context, not competition
How the reported effect sizes compare in published literature
These are independent studies in different populations; read them as context for scale, not as a ranking.
percentage points
Reported improvements in flow-mediated dilation across separate published studies.
m/s reduction
Reported reductions in pulse wave velocity across separate published studies.
mmHg reduction
Reported reductions in systolic blood pressure across separate published studies.
These values come from separately published studies and are not head-to-head comparisons. Populations, baseline health, intervention durations, study designs, and measurement methods differ. The chart contextualizes reported effect sizes and does not establish that NOVOS Core is clinically superior to exercise, diet, or any other intervention.
An honest nuance
Cholesterol is one lens. Actual vascular function is another.
The trial did not find meaningful changes in lipid markers, even while FMD, PWV, and systolic blood pressure differed from placebo. We think that’s worth highlighting.
Lipid panels and vascular-function measures describe different aspects of cardiovascular biology. FMD, PWV, and blood pressure measure the actual organ function, whereas molecules like LDL are associated with damage over the long term at high exposure.
NOVOS Core is not a lipid-lowering product and should not be used in place of cholesterol management prescribed by a healthcare professional.
Why a formulation, not an ingredient
Aging isn’t one pathway, so Core doesn’t target one.
NOVOS Core combines 12 ingredients selected to address multiple biological pathways associated with aging. What was tested clinically was the complete formulation, not any single component in isolation.
Endothelial & vessel signaling
Ingredients with research related to nitric-oxide signaling and the normal processes involved in healthy vessel dilation and blood-flow regulation.
Oxidative balance
Polyphenols and antioxidant nutrients that help support normal cellular defenses against oxidative stress.
Healthy aging pathways
Ingredients researched in relation to cellular stress-response, metabolic, and other biological pathways involved in healthy aging.
Protein & tissue integrity
Ingredients researched for their roles in normal protein maintenance and biological processes relevant to healthy tissue structure over time.
Mineral & electrolyte balance
Minerals with established roles in normal muscle function, electrolyte balance, and healthy vascular tone, including magnesium.
Connective-tissue support
Nutrients involved in normal collagen formation and the maintenance of healthy connective tissue.
These pathways reflect established nutrient functions and ingredient-level research used to inform the formulation. The trial evaluated the finished formula and did not determine which biological mechanism or individual ingredient was responsible for the observed vascular effects.
Award-winning formulation
Available at
1,331 customer reviews of NOVOS Core
Recommended by 2,000+ verified doctors & clinicians
Over 15 million NOVOS doses served
50,000+ people investing in their longevity
Part of my daily routine
“I don't think I've felt this good in years. Energy from morning to bedtime, and I like knowing the product itself has been studied rather than just its ingredients.”
Endurance and calm
“A week in and I'm already impressed. I feel calm, clear-headed, and I have more endurance into the evening hours.”
Over a year in
“I've been taking NOVOS Core for over a year now. I've never felt more energized or focused throughout the day.”
Focus and stamina
“My focus has sharpened and my energy level has markedly improved. In general I feel more optimistic about the decades ahead.”
Scientific advisory board
Formulated with input from leading longevity researchers.
Start today
One daily drink, built for the long run.
- 30 daily sachets per box
- Free shipping on subscriptions
- Pause, change flavor, or cancel anytime
- 30-day satisfaction guarantee
Choose your plan
Flavor
$950 billed upfront · Secure checkout on novoslabs.com
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Straight answers
Questions worth asking
Why should I think about cardiovascular health if I'm healthy?
Cardiovascular disease typically develops over decades. New 2026 ACC/AHA guidance now recommends estimating both 10- and 30-year cardiovascular risk beginning at age 30. Supporting cardiovascular health early is about maintaining healthy function and understanding long-term risk before disease becomes clinically obvious.
Is NOVOS Core a treatment for heart disease?
No. NOVOS Core is a dietary supplement designed to support healthy aging and normal vascular function. It is not intended to diagnose, treat, cure, or prevent cardiovascular disease, heart attack, stroke, hypertension, or any other disease.
Was NOVOS Core actually clinically studied?
Yes. The complete finished NOVOS Core formulation was evaluated in a randomized, double-blind, placebo-controlled human trial conducted by researchers at the University of Surrey in generally healthy adults aged 40+. The study evaluated vascular-function biomarkers including FMD, PWV, and systolic blood pressure. The manuscript is currently under peer review. The trial did not assess heart attacks, strokes, cardiovascular mortality, or disease prevention.
What is FMD?
Flow-mediated dilation measures how well an artery expands in response to increased blood flow. It is widely used in vascular research as a non-invasive measure of endothelial function. NOVOS Core showed a +2.9 percentage-point placebo-adjusted difference at six months.
What is PWV?
Pulse wave velocity measures the speed at which a pressure wave travels through the arteries. Stiffer arteries transmit the wave faster. NOVOS Core showed a −1.18 m/s placebo-adjusted difference at six months. Population data suggest PWV tends to worsen with age, but the NOVOS result should not be interpreted as proof that Core reversed a specific number of years of aging.
What happened to blood pressure?
The study observed a −6.1 mmHg placebo-adjusted difference in systolic blood pressure at six months. Importantly, participants began and remained within the normal blood-pressure range. NOVOS Core should not be presented as a treatment for hypertension.
Did NOVOS Core lower cholesterol?
The study did not find meaningful lipid changes, despite differences in FMD, PWV, and systolic blood pressure versus placebo. Cholesterol-related biomarkers and vascular-function biomarkers measure different aspects of cardiovascular health and should be viewed as complementary.
Does this mean NOVOS Core prevents heart attacks or strokes?
No. The clinical trial measured vascular-function biomarkers. It was not designed or powered to determine whether NOVOS Core reduces heart attacks, strokes, cardiovascular mortality, or cardiovascular-disease incidence.
Can I take NOVOS Core instead of a statin or blood-pressure medication?
No. If your healthcare professional has prescribed medication, do not stop or replace it with NOVOS Core without discussing it with them. Dietary supplements do not replace medically indicated treatment.
What else should I do for cardiovascular health?
Evidence-based fundamentals include regular physical activity, a heart-healthy dietary pattern such as Mediterranean-style eating, healthy sleep, avoiding tobacco, maintaining metabolic health, knowing relevant cardiovascular risk markers, and following appropriate medical guidance. NOVOS Core should be viewed as an additional layer, not a replacement for these fundamentals.
How long was Core studied?
Six months of daily supplementation.
What age group was studied?
Generally healthy adults aged 40 and older. The trial's findings should not be extrapolated as direct clinical proof in younger adults.
Longevity & Cardiovascular Health
The decades ahead are built by what you do now.
NOVOS Core supports healthy vascular function as part of a longevity-first routine, studied as the finished product in a randomized, placebo-controlled trial.
Important information
These statements have not been evaluated by the Food and Drug Administration. NOVOS Core is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease, including cardiovascular disease, heart attack, stroke, or hypertension.
The clinical trial referenced on this page evaluated biomarkers of vascular function in generally healthy adults aged 40 and older. It did not evaluate cardiovascular events, cardiovascular mortality, or disease incidence, and its findings should not be extrapolated to younger adults or to people with diagnosed cardiovascular disease.
These values come from separately published studies and are not head-to-head comparisons. Populations, baseline health, intervention durations, study designs, and measurement methods differ. The chart contextualizes reported effect sizes and does not establish that NOVOS Core is clinically superior to exercise, diet, or any other intervention.
References
- Heiss C, et al. Effects of a multi-ingredient longevity supplement on vascular function: a randomized, double-blind, placebo-controlled trial. SSRN preprint (manuscript under peer review). ClinicalTrials.gov NCT06145087.
- 2026 ACC/AHA guidance on cardiovascular risk assessment, including 10-year and 30-year risk estimation beginning at age 30.
- Thijssen DHJ, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. European Heart Journal.
- Vlachopoulos C, et al. Prediction of cardiovascular events and all-cause mortality with arterial stiffness measured by pulse wave velocity. Journal of the American College of Cardiology.
- Comparison values are drawn from separately published meta-analyses and randomized trials of dietary, exercise, and nutraceutical interventions.